Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 110, Issue 1, Pages 83-93
Publisher
Springer Nature
Online
2013-11-27
DOI
10.1038/bjc.2013.695
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Reovirus Activates Human Dendritic Cells to Promote Innate Antitumor Immunity
- (2014) Fiona Errington et al. JOURNAL OF IMMUNOLOGY
- Multifaceted Therapeutic Targeting of Ovarian Peritoneal Carcinomatosis Through Virus-induced Immunomodulation
- (2013) Shashi Gujar et al. MOLECULAR THERAPY
- Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer
- (2012) Jae-Sung Kim et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase II Study of Gemcitabine and Docetaxel in Recurrent Platinum Resistant Ovarian Cancer
- (2012) Agustin A. Garcia et al. CANCER INVESTIGATION
- Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies
- (2012) E. M. Karapanagiotou et al. CLINICAL CANCER RESEARCH
- Randomized, Phase III Study of Gemcitabine or Erlotinib Maintenance Therapy Versus Observation, With Predefined Second-Line Treatment, After Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Non–Small-Cell Lung Cancer
- (2012) Maurice Pérol et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Study Comparing Paclitaxel/Cisplatin/ Gemcitabine and Gemcitabine/Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Cancer Without Prior Systemic Therapy: EORTC Intergroup Study 30987
- (2012) Joaquim Bellmunt et al. JOURNAL OF CLINICAL ONCOLOGY
- NK Cell Response to Vaccinia Virus Is Regulated by Myeloid-Derived Suppressor Cells
- (2012) C. Fortin et al. JOURNAL OF IMMUNOLOGY
- Myeloid-Derived Suppressor Cells Regulate Natural Killer Cell Response to Adenovirus-Mediated Gene Transfer
- (2012) J. Zhu et al. JOURNAL OF VIROLOGY
- A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma
- (2011) Andrea E. Wahner Hendrickson et al. GYNECOLOGIC ONCOLOGY
- Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-kappaB mediated and supports innate and adaptive anti-tumour immune priming
- (2011) Lynette Steele et al. Molecular Cancer
- Precise Scheduling of Chemotherapy Primes VEGF-producing Tumors for Successful Systemic Oncolytic Virotherapy
- (2011) Timothy Kottke et al. MOLECULAR THERAPY
- Oncolytic Virus-initiated Protective Immunity Against Prostate Cancer
- (2011) Shashi A Gujar et al. MOLECULAR THERAPY
- A Phase I Study of the Combination of Intravenous Reovirus Type 3 Dearing and Gemcitabine in Patients with Advanced Cancer
- (2010) M. P. Lolkema et al. CLINICAL CANCER RESEARCH
- Current status of immunological therapies for prostate cancer
- (2010) Emmanuel S Antonarakis et al. CURRENT OPINION IN UROLOGY
- Ovarian cancer immunotherapy: opportunities, progresses and challenges
- (2010) Bei Liu et al. Journal of Hematology & Oncology
- Characterization of Cytokine-Induced Myeloid-Derived Suppressor Cells from Normal Human Peripheral Blood Mononuclear Cells
- (2010) M. G. Lechner et al. JOURNAL OF IMMUNOLOGY
- Reovirus Virotherapy Overrides Tumor Antigen Presentation Evasion and Promotes Protective Antitumor Immunity
- (2010) S. A. Gujar et al. MOLECULAR CANCER THERAPEUTICS
- Update: Immunological Strategies for Prostate Cancer
- (2010) Charles G. Drake et al. Current Urology Reports
- Human leukocyte antigen class I expression is an independent prognostic factor in advanced ovarian cancer resistant to first-line platinum chemotherapy
- (2009) M Shehata et al. BRITISH JOURNAL OF CANCER
- Synergistic Effects of Oncolytic Reovirus and Cisplatin Chemotherapy in Murine Malignant Melanoma
- (2009) H. S. Pandha et al. CLINICAL CANCER RESEARCH
- Improved Systemic Delivery of Oncolytic Reovirus to Established Tumors Using Preconditioning with Cyclophosphamide-Mediated Treg Modulation and Interleukin-2
- (2009) T. Kottke et al. CLINICAL CANCER RESEARCH
- Immune-Mediated Antitumor Activity of Reovirus Is Required for Therapy and Is Independent of Direct Viral Oncolysis and Replication
- (2009) R. J. Prestwich et al. CLINICAL CANCER RESEARCH
- Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice
- (2009) Hanh K. Le et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
- (2009) S. Ostrand-Rosenberg et al. JOURNAL OF IMMUNOLOGY
- Tumor Infection by Oncolytic Reovirus Primes Adaptive Antitumor Immunity
- (2008) R. J. Prestwich et al. CLINICAL CANCER RESEARCH
- Cyclophosphamide Facilitates Antitumor Efficacy against Subcutaneous Tumors following Intravenous Delivery of Reovirus
- (2008) J. Qiao et al. CLINICAL CANCER RESEARCH
- HLA Class I Antigen Processing Machinery Component Expression and Intratumoral T-Cell Infiltrate as Independent Prognostic Markers in Ovarian Carcinoma
- (2008) L. Y. Han et al. CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More